Epic Sciences Gets $13M For Cancer Diagnostics

San Diego-based Epic Sciences, a firm developing cancer diagnostics technology, announced today that it has raised $13M in a Series B equity round. The round came from Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, along with individuals. Kim Kamdar of Domain joins the company's board with the funding. Epic Sciences is developing diagnostic tests using molecular characterization of tumor cells in a blood stream, as a way to detect caner and monitor cancer treatments. The firm said the new funds will go towards research and development operations, as well as commercialization of its platform. Epic Sciences technology is licensed from The Scripps Research Institute. More information »